[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# $vtyx

Ventyx Biosciences ($VTYX) is seeing increased social media attention following positive Phase X data for its lead drug VTX3232, with potential for a Sanofi partnership also driving interest. However, concerns remain regarding its efficacy in obesity indications and the reliance on biomarker data over long-term outcomes.

### About $vtyx
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory diseases.  

### Insights
- $vtyx posts created is up XXXXX% from the previous week.

### Engagements: XXXXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$vtyx/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$vtyx/time-series/interactions.tsv)  
Current Value: XXXXX  
Daily Average: XXXXX  
X Week: XXXXXX -XX%  
X Month: XXXXXXX -XX%  
X Months: XXXXXXXXX +163%  
X Year: XXXXXXXXX -XXXX%  
1-Year High: XXXXXXX on 2025-10-23  
1-Year Low: XX on 2025-09-10  

Engagements by network (24h):
Reddit: XX
X: XXXXX
YouTube: X

  
  
### Mentions: XX (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$vtyx/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$vtyx/time-series/posts_active.tsv)  
Current Value: XX  
Daily Average: XX  
X Week: XXX -XXXX%  
X Month: XXX -XX%  
X Months: XXXXX +313%  
X Year: XXXXX +118%  
1-Year High: XXXXX on 2025-10-24  
1-Year Low: X on 2025-09-13  

Mentions by network (24h):
Reddit: XX
X: XXX
YouTube: X

  
  
### Creators: XX (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$vtyx/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$vtyx/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning $vtyx in the last XX hours which is up XX% from XX in the previous XX hours
Daily Average: XX  
X Week: XX +7.90%  
X Month: XXX -XX%  
X Months: XXXXX +507%  
X Year: XXXXX +576%  
1-Year High: XXXXX on 2025-10-24  
1-Year Low: X on 2025-09-13  

The most influential creators that mention $vtyx in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@Andre_AGTC](/creator/twitter/Andre_AGTC)           | X    | XXXXX     | X     | XXX         |
| [@BOSSTRADING0](/creator/twitter/BOSSTRADING0)       | X    | XXX       | X     | XXX         |
| [@StockTickerZone](/creator/twitter/StockTickerZone) | X    | XXXXX     | X     | XXX         |

[View More](/list/creators/$vtyx/100)
  
  
### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$vtyx/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$vtyx/time-series/sentiment.tsv)  
Current Value: XX%  
Daily Average: XX%  
X Week: XX% -XX%  
X Month: XX% -X%  
X Months: XX% -XX%  
X Year: XX% +20%  
1-Year High: XXX% on 2024-12-29  
1-Year Low: XX% on 2025-02-21  

Most Supportive Themes:
- Positive Phase X Data for VTX3232: (30%) Ventyx Biosciences' lead drug, VTX3232, has shown positive Phase X results, particularly in reducing hsCRP, a key inflammation marker. This data suggests potential for oral therapies in inflammatory diseases and cardiovascular risk reduction.
- Sanofi Partnership Potential: (25%) Sanofi has a right of first refusal (ROFN) on Ventyx's lead asset and has previously invested in the company. This suggests a potential acquisition or partnership, which is a significant catalyst for VTYX.
- Upcoming Pericarditis Data: (20%) Upcoming Phase X data for VTX2735 for Recurrent Pericarditis is anticipated, with expectations of positive results due to similar endpoints to previous successful trials.
  
Most Critical Themes:
- Obesity Indication Concerns: (15%) While VTX3232 showed positive biomarker reductions, some analysts express skepticism about its efficacy in obesity, particularly if it relies solely on weight loss. The market may be over-indexing on sheer weight loss percentage.
- Biomarker vs. Outcomes Data: (10%) The current positive data for VTX3232 is based on biomarkers (hsCRP) over XX weeks, not long-term clinical outcomes. This introduces an element of uncertainty regarding its ultimate impact.
  

### Top $vtyx Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$VTYX new alerts have been posted in the last hours-"  
[X Link](https://x.com/AnitaMc26910087/status/1997876636822524091) [@AnitaMc26910087](/creator/x/AnitaMc26910087) 2025-12-08T03:51Z XXX followers, XX engagements


"@_Biotech_iQ $vtyx Great table. XXX can indeed go head to head with XXX. If they can secure a partner and bring this forward the valuation gap is huge. CEO did hint they also have 'other assets' to bring forward in Piper sharing. And 3232 should decided in about a month. #jpm26"  
[X Link](https://x.com/Longroaderstar/status/1997856690977566995) [@Longroaderstar](/creator/x/Longroaderstar) 2025-12-08T02:32Z XXX followers, XXX engagements


"@_Biotech_iQ VTYX looks quite superior from this data. I am long $VTYX because they also have several significant readouts coming (VTX 2735).not to mention a decision by Sanofi to partner on VTYX 3232 by January 2026 (estimate per Wells Fargo)"  
[X Link](https://x.com/FWCWeather/status/1997794547808768166) [@FWCWeather](/creator/x/FWCWeather) 2025-12-07T22:25Z XXX followers, XXX engagements


"$VTYX S1P1 vs $ABVX miR-124 Data looks comparable but VTYX program is practically on hold until they found a partner While data were promising they probably decided that going after NLRP3 is less risky Note that S1P1 & miR-124 both might have theoretically cardiac issues"  
[X Link](https://x.com/Andre_AGTC/status/1997790820750246051) [@Andre_AGTC](/creator/x/Andre_AGTC) 2025-12-07T22:10Z 6222 followers, 5797 engagements